Does Glaukos (GKOS) Using Epioxa at ASCRS Hint at a Broader Corneal-Health Strategy Shift? [Yahoo! Finance]
Glaukos Corporation (GKOS)
Last glaukos corporation earnings: 2/27 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.glaukos.com/investors/investor-overview/default.aspx
Company Research
Source: Yahoo! Finance
Refractive Surgery annual meeting in Washington, D.C., including an educational symposium introducing Epioxa, the first and only FDA-approved, epithelium-on, oxygen-enriched corneal cross-linking treatment. This visibility among cataract and refractive surgeons, combined with new clinical outcomes and device data in glaucoma and corneal health, could influence how clinicians view Glaukos' role across multiple ophthalmic treatment areas. We'll now examine how the introduction of Epioxa at ASCRS may reshape Glaukos' investment narrative and its positioning in corneal health. Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. Glaukos Investment Narrative Recap To own Glaukos, you need to believe its glaucoma and corneal portfolios can justify today's premium valuation despite ongoing losses and heavy R&D spend. The ASCRS spotlight on Epioxa raises visi
Show less
Read more
Impact Snapshot
Event Time:
GKOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GKOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GKOS alerts
High impacting Glaukos Corporation news events
Weekly update
A roundup of the hottest topics
GKOS
News
- Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29Business Wire
- Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual MeetingBusiness Wire
- Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus CareBusiness Wire
- Should Glaukos' (GKOS) Big 2026 Sales Target and ESOP Shelf Filing Require Action From Investors? [Yahoo! Finance]Yahoo! Finance
GKOS
Earnings
- 2/17/26 - Miss
GKOS
Sec Filings
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- GKOS's page on the SEC website